Media headlines about Karyopharm Therapeutics (NASDAQ:KPTI) have been trending positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Karyopharm Therapeutics earned a coverage optimism score of 0.27 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.7055472368471 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
A number of equities research analysts recently weighed in on KPTI shares. HC Wainwright restated a “buy” rating and set a $23.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, November 15th. started coverage on Karyopharm Therapeutics in a research report on Wednesday, November 15th. They set a “buy” rating and a $23.00 price objective on the stock. BidaskClub upgraded Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. Royal Bank of Canada restated a “buy” rating and set a $15.00 price objective on shares of Karyopharm Therapeutics in a research report on Friday, November 3rd. Finally, Robert W. Baird restated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $17.33.
Shares of Karyopharm Therapeutics (KPTI) opened at $14.59 on Wednesday. Karyopharm Therapeutics has a 52-week low of $7.48 and a 52-week high of $15.61. The company has a market capitalization of $742.01, a PE ratio of -5.51 and a beta of 4.11.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.